Japanese encephalitis: Development of new candidate vaccines

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 2, 2006, Pages 313-324

  Bharati, Kaushik ^a   Vrati, Sudhanshu ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Immunogenicity; Peptide; Recombinant virus; Virus like particle

Indexed keywords

DNA VACCINE; GELATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INACTIVATED VACCINE; INTERLEUKIN 2; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANGIONEUROTIC EDEMA; BACULOVIRUS EXPRESSION SYSTEM; CANARYPOX VIRUS; CELL CULTURE; CHINA; CLINICAL TRIAL; DIZZINESS; DRUG COST; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG UTILIZATION; EPIDEMIC; EPIDEMIC ENCEPHALITIS; ERYTHEMA; FEVER; FLAVIVIRUS; GOOD MANUFACTURING PRACTICE; HEADACHE; HUMAN; INDIA; INJECTION SITE REACTION; JAPANESE ENCEPHALITIS VIRUS; MALAISE; MOSQUITO; MOUSE; NONHUMAN; PATHOGENESIS; RESPIRATORY DISTRESS; REVIEW; SOUTHEAST ASIA; SWELLING; URTICARIA; VACCINIA VIRUS; VERO CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS ENCEPHALITIS; VIRUS IMMUNITY; VIRUS TRANSMISSION; YELLOW FEVER FLAVIVIRUS;

ANIMALS; CULICIDAE; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 33646174031     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.2.313     Document Type: Review

References (91)

1. WHO. Japanese encephalitis vaccines. Wkly Epidemiol. Rec. 73, 337-344 (1998).
2. Hanna JN, Ritchie SA, Phillips DA et al. Japanese encephalitis in north Queensland, Australia, 1998. Med. J. Aust. 170, 533-536 (1999).
3. van den Hurk AF, Johansen CA, Zborowski P et al. Mosquito host-feeding patterns and implications for Japanese encephalitis virus transmission in northern Australia and Papua New Guinea. Med. Vet. Entomol. 17, 403-411 (2003).
4. Igarashi A, Tanaka M, Morita K et al. Detection of West Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol. Immunol. 38, 827-830 (1994).
5. Halstead SB, Jacobson J. Japanese encephalitis. Adv. Virus Res. 61, 103-138 (2003)
6. Sumiyoshi H, Mori C, Fuke I et al. Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology 161, 497-510 (1987).
7. Vrati S, Girl RK, Razdan A et al. Complete nucleotide sequence of an Indian strain of Japanese encephalitis virus: sequence comparison with other strains and phylogenetic analysis. Am. J. Trop. Med. Hyg. 61, 677-680 (1999).
8. Chambers TJ, Hahn CS, Galler R et al. Flavivirus genome organization, expression and replication. Ann. Rev Microbiol. 44, 649 (1990).
9. Guirakhoo F, Bolin RA, Roehrig JT. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 191, 921-931 (1992).
10. Bray M, Lai CJ. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 185, 505-508 (1991).
11. Gould EA, Buckley A, Barrette ADT et al. Neutralizing (54 K) and non-neutralizing (54 K and 58 K) monoclonal antibodies against the structural and nonstructural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67, 591-596 (1986).
12. Hawkes RA, Roehrig JT, Hunt AR et al. Antigenic structure of the Murray Valley encephalitis virus E glycoprotein. J. Gen. Virol. 69, 1105-1109 (1988).
13. Kimura-Kiroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration of monoclonal antibodies. J. Immunol. 141, 3606-3610 (1988).
14. Lee JM, Crooks AJ, Stephenson JR. The synthesis and maturation of a non-structural extracellular antigen from tick-borne encephalitis virus and its relationship to the intracellular NS1 protein. J. Gen. Virol. 70, 335 (1989).
15. Cardiff RD, Lund JK. Distribution of dengue-2 antigens by electron immunocytochemistry. Infect. Immun. 13, 1699-1709 (1976).
16. Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 68(Pt 3). 853-857 (1987).
17. Schlesinger JJ, Foltzer M, Chapman S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192, 132-141 (1993).
18. Nestorowicz A, Chambers TJ, Rice CM. Mutagenesis of the yellow fever virus NS2A/B cleavage site: effects on proteolytic processing, viral replication, and evidence for alternative processing of the NS2A protein. Virology 199, 114 (1994).
19. Wengler G, Wengler G. Cell-associated West Nile flavivirus is covered with E+ pre-M protein heterodimers which are destroyed and reorganized by proteolytic cleavage during virus release. J. Virol. 63, 2521-2526 (1989).
20. Murthy HM, Judge K, DeLucas L et al. Crystal structure of dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. J. Mol. Biol. 301, 759-767 (2000).
21. Bartelma G, Padmanabhan R. Expression, purification, and characterization of the RNA 5′-triphosphatase activity of dengue virus type 2 nonstructural protein 3. Virology 299, 122-132 (2002).
22. Westaway EG, Mackenzie JM, Khromykh AA. Replication and gene function in Kunjin virus. Curr. Top. Microbiol. Immunol. 267, 323-351 (2002).
23. Mandl CW, Heinz FX, Stockl E et al. Genome sequence of tick-borne encephalitis virus (Western subtype) and comparative analysis of nonstructural proteins with other flaviviruses. Virology 173, 291-301 (1989).
24. Chen WR, Tesh RB, Rico-Hesse R. Genetic variation of Japanese encephalitis virus in nature. J. Gen. Virol. 71, 2915-2922 (1990).
25. Chen WR, Rico-Hesse R, Tesh RB. A new genotype of Japanese encephalitis virus from Indonesia. Am. J. Trop. Med. Hyg. 47, 61-69 (1992).
26. Uchil PD, Satchidanandam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent. Am. J. Trop. Med. Hyg. 65, 242-251 (2001).
27. Sohn YM. Japanese encephalitis immunization in South Korea: past, present, and future. Emerg. Infect. Dis. 6, 17-24 (2000).
28. Ku CC, King CC, Lin CY et al. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. J. Med. Virol. 44, 122-131 (1994).
29. Hoke CH, Nisalak A, Sangawhipa N et al. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319, 608-614 (1988).
30. Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol. Allergy Clin. N. Am. 23, 665-697 (2003).
31. Plesner AM, Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 15, 1239-1243 (1997).
32. Sakaguchi M, Yoshida M, Kuroda W et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 15, 121-122 (1997).
33. Tsai TF, Chang G-J, Yu Y-X. Japanese encephalitis vaccines. In: Vaccines. Plotkin SA, Orenstein WA (Eds), WB Saunders Company, PA, USA, 672-710 (1999).
34. Ao J, Yu F, Tang YS et al. Selection of a better immunogenic and highly attenuated live vaccine virus strain of Japanese encephalitis. II. Safety and immunogenicity of live vaccine SA 14-14-2 observed in inoculated children. Chin. J. Microbiol. Immunol. 3, 245-248 (1983).
35. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 18(Suppl. 2), 1-25 (2000).
36. Xin YY, Ming ZG, Peng GY et al. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am. J. Trop. Med. Hyg. 39, 214-217 (1988).
37. Liu ZL, Hennessy S, Strom BL et al, Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J. Infect. Dis. 176, 1366-1369 (1997).
38. Bista MB, Banerjee MK, Shin SH et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358, 791-795 (2001).
39. Sohn YM, Park MS, Rho HO et al. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine 17, 2259-2264 (1999).
40. Montagnon BJ, Vincent-Falquet JC, Saluzzo JF. Experience with Vero cells at Pasteur Merieux Connaught. Dev. Biol Stand. 98, 137-140 (1999).
41. Srivastava AK, Putnak JR, Lee SH et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19, 4557-4565 (2001).
42. Sugawara K, Nishiyama K, Ishikawa Y et al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30, 303-314 (2002).
43. Kuzuhara S, Nakamura H, Hayashida K et al. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 21, 4519-4526 (2003).
44. Appaiahgari MB, Vrati S. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine 22, 3669-3675 (2004).
45. Seif SA, Morita K, Matsuo S et al. Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis E protein expressed in recombinant Escherichia coli system. Vaccine 13, 1515-1521(1995).
46. Seif SA, Morita K, Igarashi A. A 27 amino acid coding region of JE virus E protein expressed in E. coli as fusion protein with glutathione-S-transferase elicit neutralizing antibody in mice. Virus Res. 43, 91-96 (1996).
47. Saini M, Vrati S. A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J. Virol. 77, 3487-3494 (2003).
48. Wu SC, Yu CH, Lin CW et al. The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. Vaccine 21, 2516-2522 (2003).
49. Rauthan M, Kaur R, Appaiahgari MB et al. Oral immunization of mice with Japanese encephalitis virus envelope protein synthesized in Escherichia coli induces anti-viral antibodies. Microbes Infect. 6, 1305-1311 (2004).
50. Matsuura Y, Miyamoto M, Sato T et al. Characterization of Japanese encephalitis virus envelope protein expressed by recombinant baculovirus. Virology 173(2), 674-682 (1989).
51. McCown J, Cochran M, Putnak R et al. Protection of mice against lethal Japanese encephalitis with a recombinant baculovirus vaccine. Am. J. Trop. Med. Hyg. 42, 491-499 (1990).
52. Yang DK, Kweon CH, Kim BH et al. Immunogenicity of baculovirus expressed recombinant proteins of Japanese encephalitis virus in mice. J. Vet. Sci. 6, 125-133 (2005).
53. Konishi E, Pincus S, Paoletti E et al. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 188, 714-720 (1992).
54. Konishi E, Win KS, Kurane I et al. Particulate vaccine candidate for Japanese encephalitis induces long-lasting virus-specific memory T lymphocytes in mice. Vaccine 15, 281-286 (1997).
55. Konishi E, Fujii A, Mason PW. Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J. Virol. 75, 2204-2212 (2001).
56. Hunt AR, Cropp CB, Chang GJ. A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen. J. Virol. Methods 97, 133-149 (2001).
57. Kojima A, Yasuda A, Asanuma H et al. Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus E protein for a second-generation subunit vaccine. J. Virol. 77, 8745-8755 (2003).
58. Konishi E, Pincus S, Beneditto ALF et al. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology 185, 401-410 (1991).
59. Jan LR, Yang CS, Henchal LS et al. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein. Am. J Trop. Med. Hyg. 48, 412-423 (1993).
60. Tartaglia J, Perkus ME, Taylor J et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232 (1992).
61. Konishi E, Pincus S, Paoletti E et al. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of japanese encephalitis virus prevents JEV viremia in swine. Virology 190, 454-458 (1992).
62. Nam JH, Wyatt LS, Chae SL et al. Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine 17, 261-268 (1999).
63. Taylor J, Trimarchi C, Weinberg R et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 9, 190-193 (1991).
64. Konishi E, Pincus S, Paoletti E et al. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine 12, 633-638 (1994).
65. Raengsakulrach B, Nisalak A, Gettayacamin M et al. Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys. Am. J. Trop. Med. Hyg. 60, 343-349 (1999).
66. Kanesa-Thasan N, Smucny JJ, Hoke CHJ et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19, 483-491 (2000).
67. Appaiahgari MB, Saini M, Rauthan M, Jyoti, Vrati S. Immunization with recombinant adenovirus synthesizing secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect. 8, 92-104 (2006).
68. Chambers TJ, Nestorowicz A, Mason PW et al. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73, 3095-3101 (1999).
69. Guirakhoo F, Zhang ZX, Chambers TJ et al. Immunogenecity, genetic stability, and protective efficacy of a recombinant chimaeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257, 363-372 (1999).
70. Monath TP, Levenbook I, Soike K et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 74, 1742-1751 (2000).
71. Arroyo J, Guirakhoo F, Fenner S et al. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J. Virol. 75, 934-942 (2001).
72. Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20, 1004-1018 (2002).
73. Monath TP. Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188, 1213-1230 (2003).
74. Konishi E, Yamaoka M, Khin SW et al. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J. Virol. 72, 4925-4930 (1998).
75. Konishi E, Yamaoka M, Kurane I et al. Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine. Virology 268, 49-55 (2000).
76. Chang GJ, Hunt AR, Davis B. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J. Virol. 74, 4244-4252 (2000).
77. Ashok MS, Rangarajan PN. Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies. Vaccine 18, 68-75 (1999).
78. Chen HW, Pan CH, Liau MY et al. Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines. J. Virol. 73, 10137-10145 (1999).
79. Konishi E, Yamaoka M, Khin SW et al. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J. Virol. 73, 5527-5534 (1999).
80. Kaur R, Sachdeva G, Vrati S. Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein. J. Infect. Dis. 185, 1-12 (2002).
81. Lin YL, Chen LK, Liao CL et al. DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J. Virol. 72, 191-200 (1998).
82. Schlesinger JJ, Brandriss MW, Cropp CB et al. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 60, 1153-1155 (1986).
83. Konishi E, Ajiro N, Nukuzuma C et al. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine 21, 3675-3683 (2003).
84. Pan CH, Chen HW, Huang HW et al. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. J. Virol. 75, 11457-11463 (2001).
85. Kaur R, Rauthan M, Vrati S. Immunogenicity in mice of a cationic microparticle-adsorbed plasmid DNA encoding Japanese encephalitis virus envelope protein. Vaccine 22, 2776-2782 (2004).
86. Zhao Z, Wakita T, Yasui K. Inoculation of plasmids encoding Japanese encephalitis virus PrM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice. J. Virol. 77, 4248-4260 (2003).
87. Bharati K, Appaiahgari MB, Vrati S. Effect of cytokine-encoding plasmid delivery on immune response to Japanese encephalitis virus DNA vaccine in mice. Microbiol. Immunol. 49, 349-353 (2005).
88. Nukuzuma C, Ajiro N, Wheeler CJ et al. Enhancing effect of vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice. Viral Immunol. 16, 183-189 (2003).
89. Wu CJ, Lee SC, Huang HW et al. In Vivo electroporation of skeletal muscles increases the efficacy of Japanese encephalitis virus DNA vaccine. Vaccine 22, 1457-1464 (2004).
90. Tanabayashi K, Mukai R, Yamada A et al. Immunogenicity of a Japanese encephalitis DNA vaccine candidate in cynomolgus monkeys. Vaccine 21, 2338-2345 (2003).
91. Kumar P, Krishna VD, Sulochana P et al. Cell-mediated immune responses in healthy children with a history of subclinical infection with Japanese encephalitis virus: analysis of CD4+ and CD8+ T cell target specificities by intracellular delivery of viral proteins using the human immunodeficiency virus Tat protein transduction domain. J. Gen. Virol. 85, 471-482 (2004).